| 1 |
34302727 | Lenvatinib Targets PDGFR-β Pericytes and Inhibits Synergy With Thyroid Carcinoma Cells: Novel Translational Insights. | 2021 Nov 19 |
4 |
| 2 |
34428101 | Lenvatinib: an investigational agent for the treatment of differentiated thyroid cancer. | 2021 Sep |
1 |
| 3 |
32817132 | Phase II study of lenvatinib for metastatic colorectal cancer refractory to standard chemotherapy: the LEMON study (NCCH1503). | 2020 Aug |
1 |
| 4 |
33198671 | Phase 2 study of lenvatinib monotherapy as second-line treatment in unresectable biliary tract cancer: primary analysis results. | 2020 Nov 16 |
1 |
| 5 |
30685073 | Managing the adverse events associated with lenvatinib therapy in radioiodine-refractory differentiated thyroid cancer. | 2019 Feb |
1 |
| 6 |
29468981 | Lenvatinib in the Therapy of Aggressive Thyroid Cancer: State of the Art and New Perspectives with Patents Recently Applied. | 2018 |
1 |
| 7 |
29517103 | Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo. | 2018 May |
1 |
| 8 |
29615459 | Genetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid Cancers. | 2018 Jul 1 |
1 |
| 9 |
29656442 | Treatment-emergent hypertension and efficacy in the phase 3 Study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT). | 2018 Jun 1 |
2 |
| 10 |
30032643 | Lenvatinib: A Promising Molecular Targeted Agent for Multiple Cancers. | 2018 Jan-Dec |
2 |
| 11 |
30069768 | Lenvantinib: A Tyrosine Kinase Inhibitor of VEGFR 1-3, FGFR 1-4, PDGFRα, KIT and RET. | 2018 |
2 |
| 12 |
30220234 | Lenvatinib as a therapy for unresectable hepatocellular carcinoma. | 2018 Nov |
1 |
| 13 |
26678514 | Lenvatinib: Role in thyroid cancer and other solid tumors. | 2016 Jan |
2 |
| 14 |
26867945 | Lenvatinib: A Review in Refractory Thyroid Cancer. | 2016 Feb |
1 |
| 15 |
27799794 | Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancer. | 2016 |
1 |
| 16 |
27817859 | [Lenvatinib in radioiodine refractory thyroid carcinomas]. | 2016 Nov |
1 |
| 17 |
25795101 | Lenvatinib: first global approval. | 2015 Apr |
2 |
| 18 |
26484847 | Drug safety evaluation of lenvatinib for thyroid cancer. | 2015 |
1 |
| 19 |
25197551 | Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage. | 2014 |
1 |
| 20 |
25295214 | Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models. | 2014 |
2 |